

Cancer Measures

	Numerator	Denominator	Comments	Goal	PECS
REQUIRED MEASURES					
Patients with documentation of self-management goal setting	Number of patients (women \geq 21yo and men \geq 51yo) who have had documentation of self-management goal setting (shared decision making recommended) about cancer screening and follow-up in the last 12 months	Total number women \geq 21yo and men \geq 51yo in registry	Shared decision making includes 3 elements: Asking; Telling/sharing information; Identifying a plan	>70%	8A
Women \geq 42yo with mammogram in the previous 2 years	Number of women \geq 42yo with mammogram within previous 2 years	Total number of women \geq 42yo in registry	Reference 2	>70%	9B
Women \geq 21yo with pap smear within prior 3 years	Number of women \geq 21yo with pap smear within the prior 3 years	Total number of women \geq 21yo in the registry	References 4, 5, 6	>90%	9C
Adults \geq 51yo with appropriate screening for colon cancer	Number of adults \geq 51yo screened with at least one of the following: FOBT within one year, sigmoidoscopy within 5 years, colonoscopy within 10 years	Total number of adults \geq 51yo in registry	Reference 2	>70%	9D
Patients having documented notification of mammogram, pap, and colon cancer screening results within 30 days	Number of women \geq 42yo with documented notification of mammogram results within 30 days + number of women \geq 21yo with documented notification of pap results within 30 days + number of adults \geq 51yo with documented notification of colon cancer screening results within 30 days (screenings that have occurred within past 12 months)	Total number of women \geq 42yo with mammogram + number of women \geq 21yo with pap + number of adults \geq 51yo with colon cancer screening (screenings that have occurred within the past 12 months)	References 7, 8 Most based on federal regulation, mammography quality standards, expert opinions.	>90%	13B
Patients with required additional evaluation and/or treatment within the appropriate time frame	Number of women (\geq 42yo) having additional required evaluation (imaging, biopsy, clinical) within 60 days of date of abnormal mammogram + number of women (\geq 42yo) with invasive cancer or DCIS having initial treatment documented within 90 days of diagnosis + number of women (\geq 21yo) who require colposcopy having been evaluated within 90 days of the date of abnormal test + number of women (\geq 21yo) with CIN 2 & 3 having initial treatment documented within 90 days of diagnosis + number of adults (\geq 51yo) with positive FOBT having colonoscopy (or sigmoidoscopy or BE) within 60 days of date of positive FOBT + number adults (\geq 51yo) with polyp or colon cancer having initial treatment documented within 90 days of lab confirmation of diagnosis (screenings and diagnoses that have occurred within last 12 months)	Total number of women \geq 42yo with abnormal mammogram + number of women with invasive cancer or DCIS + number of women \geq 21yo requiring colposcopy + number of women with CIN 2 & 3 + number of adults \geq 51yo with positive FOBT + number of adults \geq 51yo with polyp or colon cancer (screenings and diagnoses that have occurred within last 12 months)	No 'standard of care' among all three cancers. Most recommendations based on expert opinions.	>90%	14B (Error in PECS?)

Based on Health Disparities Collaboratives Cancer Measures. Accessed 8/2/05 <http://www.healthdisparities.net/hdc/html/collaboratives.topics.cancer.aspx>

References:

1. Humphrey LL, Helfand M, Chan BKS, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventative Services Task Force. *Ann Intern Med.* 2002;137(5):347-360
2. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2002;137(2):132-41
3. MMWR
4. Lawson et al
5. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. *CA Cancer J Clin.* 2002;52:342-62
6. Benard VB, Lee NC, Piper M, Richardson L. Race-specific results of Papanicolaou testing and the rate of cervical neoplasia in the National Breast and Cervical Cancer Early Detection Program, 1991-1998 (United States). *Cancer Causes Control.* 2001 Jan;12(1):61-8
7. Herbert A, Johnson J, Patnick J. Achievable standards, benchmarks for reporting and criteria for evaluating cervical cytopathology. *Cytopathology.* 1995 Oct;6(5):301-3.
8. Schofield MJ, Sanson-Fisher R, Halpin S, Redman S. Notification and follow-up of Pap test results: current practice and women's preferences. *Prev Med.* 1994 May;23(3):276-83
9. Bigby J, Ko LK, Johnson N, David MM, Ferrer B; REACH Boston 2010 Breast and Cervical Cancer Coalition. A community approach to addressing excess breast and cervical cancer mortality among women of African descent in Boston. *Public Health Rep.* 2003 Jul-Aug;118(4):338-47.
10. Ell K, Vourlekis B, Muderspach L, Nissly J, Padgett D, Pineda D, Sarabia O, Lee PJ. Abnormal cervical screen follow-up among low-income Latinas: Project SAFe. *J Womens Health Gen Based Med.* 2002 Sep;11(7):639-51.
11. Nelson K, Geiger AM, Mangione CM. Effect of health beliefs on delays in care for abnormal cervical cytology in a multi-ethnic population. *J Gen Intern Med.* 2002 Sep;17(9):709-16.
12. Cardin VA, Grimes RM, Jiang ZD, Pomeroy N, Harrell L, Cano P. Low-income minority women at risk for cervical cancer: a process to improve adherence to follow-up recommendations. *Public Health Rep.* 2001 Nov-Dec;116(6):608-16.